Abstract
Amyotrophic lateral sclerosis (ALS) is an adult-onset motor neuron disease characterized by degeneration of motor neuron and glial activation followed by the progressive muscle loss and paralysis. Numerous distinct therapeutic interventions have been examined but currently ALS does not have a cure or an efficacious treatment for the disorder. Glutamate- induced excitotoxicity, inflammation, mitochondrial dysfunction, oxidative stress, protein aggregation, transcription deregulation, and epigenetic modifications are associated with the pathogenesis of ALS and known to be therapeutic targets in ALS. In this review, we discuss translational pharmacological studies targeting epigenetic components to ameliorate ALS. Understanding of the epigenetic mechanisms will provide novel insights that will further identify potential biological markers and therapeutic approaches for treating ALS. A combination of treatments that modulate epigenetic components and multiple targets may prove to be the most effective therapy for ALS.
Keywords: Amyotrophic lateral sclerosis, epigenetic components, HDAC inhibitor, motor neuron, transcription, therapeutics.
Current Medicinal Chemistry
Title:Therapeutic Targeting of Epigenetic Components in Amyotrophic Lateral Sclerosis (ALS)
Volume: 21 Issue: 31
Author(s): J. Lee, H. Ryu, G. Keum, Y.J. Yoon, N.W. Kowall and H. Ryu
Affiliation:
Keywords: Amyotrophic lateral sclerosis, epigenetic components, HDAC inhibitor, motor neuron, transcription, therapeutics.
Abstract: Amyotrophic lateral sclerosis (ALS) is an adult-onset motor neuron disease characterized by degeneration of motor neuron and glial activation followed by the progressive muscle loss and paralysis. Numerous distinct therapeutic interventions have been examined but currently ALS does not have a cure or an efficacious treatment for the disorder. Glutamate- induced excitotoxicity, inflammation, mitochondrial dysfunction, oxidative stress, protein aggregation, transcription deregulation, and epigenetic modifications are associated with the pathogenesis of ALS and known to be therapeutic targets in ALS. In this review, we discuss translational pharmacological studies targeting epigenetic components to ameliorate ALS. Understanding of the epigenetic mechanisms will provide novel insights that will further identify potential biological markers and therapeutic approaches for treating ALS. A combination of treatments that modulate epigenetic components and multiple targets may prove to be the most effective therapy for ALS.
Export Options
About this article
Cite this article as:
Lee J., Ryu H., Keum G., Yoon Y.J., Kowall N.W. and Ryu H., Therapeutic Targeting of Epigenetic Components in Amyotrophic Lateral Sclerosis (ALS), Current Medicinal Chemistry 2014; 21(31) . https://dx.doi.org/10.2174/0929867321666140706131825
DOI https://dx.doi.org/10.2174/0929867321666140706131825 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Therapeutic Management of COVID-19 Patients: Clinical Manifestation and Limitations
Current Pharmaceutical Design Reviewing Biochemical Implications of Normal and Mutated Huntingtin in Huntington’s Disease
Current Medicinal Chemistry The Unbiased Search of Biomarkers in Neurodegenerative Diseases
Current Pharmaceutical Biotechnology Chemistry and Biochemistry of Oxidative Stress in Neurodegenerative Disease
Current Medicinal Chemistry Dual Functional Small Molecule Probes as Fluorophore and Ligand for Misfolding Proteins
Current Organic Chemistry Alzheimer's Disease and Natural Products: Future Regimens Emerging from Nature
Current Topics in Medicinal Chemistry Immunocal® and Preservation of Glutathione as a Novel Neuroprotective Strategy for Degenerative Disorders of the Nervous System
Recent Patents on CNS Drug Discovery (Discontinued) Clinical Applications of Creatine Supplementation on Paediatrics
Current Pharmaceutical Biotechnology Tianeptine: A Novel Atypical Antidepressant that May Provide New Insights into the Biomolecular Basis of Depression
Recent Patents on CNS Drug Discovery (Discontinued) mGluRI Targets Microglial Activation and Selectively Prevents Neuronal Cell Engulfment Through Akt and Caspase Dependent Pathways
Current Neurovascular Research Monoclonal Antibodies: A Target Therapy for Multiple Sclerosis
Inflammation & Allergy - Drug Targets (Discontinued) Induction of Molecular Chaperones as a Therapeutic Strategy for the Polyglutamine Diseases
Current Pharmaceutical Biotechnology Identification of Electrophysiological Changes in Alzheimer's Disease: A Microarray Based Transcriptomics and Molecular Pathway Analysis Study
CNS & Neurological Disorders - Drug Targets NMDA Neurotransmission Dysfunction in Mild Cognitive Impairment and Alzheimers Disease
Current Pharmaceutical Design The Glutamatergic Hypothesis for Down Syndrome: The Potential Use of N-Methyl-D-Aspartate Receptor Antagonists to Enhance Cognition and Decelerate Neurodegeneration
CNS & Neurological Disorders - Drug Targets Vascular Endothelial Growth Factor in Central Nervous System Injuries – A Vascular Growth Factor Getting Nervous?
Current Neurovascular Research Minocycline and Doxycycline: More Than Antibiotics
Current Molecular Pharmacology Lewy Bodies: A Spectator or Salient Killer?
CNS & Neurological Disorders - Drug Targets Liposomes as siRNA Delivery Vectors
Current Drug Metabolism Is there a Rational Approach for Increasing Drug Specificity? Considerations on CNS Target Choice and Validation
Recent Patents on CNS Drug Discovery (Discontinued)